Novo Nordisk receives US FDA approval of ESPEROCT®

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A.


Read the full story here.

Subscribe and Get Breaking News Sent to Your Inbox!

  • White Instagram Icon
  • White Facebook Icon

© 2019- 2020 HEMO TIMES IS A SUBSIDIARY OF RARE HEALTH NETWORK, LLC